Clinical and Translational

Cancer Gene Variant Detection Using a Pre-Optimized Sample to Report Workflow

October 31, 2019

BRCA1/BRCA2 genes represent the best examples for our current understanding of the molecular genetics of cancer. Studying germline mutations in BRCA1, BRCA2, and other genes are necessary to identify novel markers associated with an increased risk of disease. While NGS testing is state of the art, many labs still struggle to optimize their NGS workflow to detect all pathogenic variants, including those challenging ones in homopolymer regions, small-to-large insertions, and deletions, as well as copy number variants down to exon level. Standardized and reproducible classification/interpretation of detected variants into pathogenic and benign to be able to compare and combine results from different labs or even different scientists presents another challenge.

In this Clinical OMICs webinar, we will present data from a pre-optimized sample extraction to variant interpretation workflow using the GeneReaderTM NGS System. Additionally, we will show the performance of the system on challenging variants using reference samples, as well as clinical samples. The findings presented in this webinar demonstrate the high level of accuracy for the GeneReader System, eliminating the need to perform time-consuming workflow optimizations.

Interested in learning more?

Click here

Speaker: Julie Deschênes, PhD


Global Product Management for Hereditary Cancer, QIAGEN

Related videos

Clinical and Translational

How to reduce your test turnaround for large panels in molecular oncology

258 views December 31, 2019

Speaker: Sheryl Elkin, CSO, N-of-One.a QIAGEN Company Interested in learning...

Clinical and Translational

LeukoVantage: A Quest/Qiagen Partnership Providing Clinical Insights Into Myeloid Malignancies

256 views December 09, 2019

The integration of next-generation sequencing (NGS) into the diagnostic...

Clinical and Translational

Increasing the efficiency of diagnostic odysseys

310 views September 16, 2019

Despite rapid cost reductions in sequencing technologies and an...

Clinical and Translational

Managing Multiple Biomarker Therapeutic Development

301 views September 12, 2019

For the past two decades, the paradigm in the field has been “one biomarker,...